Comparison of capillary blood and plasma samples for the evaluation of seroprevalence to SARS-CoV-2 antibodies by lateral flow immunoassay in a university population in Medellín, Colombia, 2020.

Objectives: The aim of this study was to estimate the seroprevalence of anti-SARS-CoV-2 antibodies using the SARS-CoV-2 antibody test in a university population. Capillary blood and plasma samples were compared and correlated with symptomatology to establish rapid treatment processes and develop a public health strategy within the community. Study design: Descriptive study of seroprevalence of anti-SARS-CoV-2 antibodies in a university population. Methods: Standardised and validated laboratory serological tests were used to assess the immune response detected in capillary blood and plasma samples. In this study, 280 participants from the University Colegio Mayor de Antioquia in the Municipality of Medellín, Colombia, were tested for SARS-CoV-2 antibodies in capillary blood and plasma samples between November 2020 and January 2021. Results: In total, 29 (11.2%) individuals had positive results for anti-SARS-CoV-2 antibodies (IgG/IgM); 28 (96.6%) had positive results in plasma samples and 11 (37.9%) in capillary blood samples. The two tests were compared, and the overall sensitivity and specificity of capillary vs plasma samples was 36.7% and 99.6%, respectively. Conclusions: Anti-SARS-CoV-2 antibodies (IgG/IgM) can be used to estimate the seroprevalence in populations, including immunity by vaccination; however, capillary blood samples should not be used to detect previous infection as they provide low sensitivity compared to plasma samples.

Type 1 and type 2 diabetes mellitus: Clinical outcomes due to COVID-19. Protocol of a systematic literature review.

INTRODUCTION: Diabetes has been associated with an increased risk of complications in patients with COVID-19. Most studies do not differentiate between patients with type 1 and type 2 diabetes, which correspond to two pathophysiological distinct diseases that could represent different degrees of clinical compromise. OBJECTIVE: To identify if there are differences in the clinical outcomes of patients with COVID-19 and diabetes (type 1 and type 2) compared to patients with COVID-19 without diabetes. METHODS: Observational studies of patients with COVID-19 and diabetes (both type 1 and type 2) will be included without restriction of geographic region, gender or age, whose outcome is hospitalization, admission to intensive care unit or mortality compared to patients without diabetes. Two authors will independently perform selection, data extraction, and quality assessment, and a third reviewer will resolve discrepancies. The data will be synthesized regarding the sociodemographic and clinical characteristics of patients with diabetes and without diabetes accompanied by the measure of association for the outcomes. The data will be synthesized regarding the sociodemographic and clinical characteristics of patients with diabetes and without diabetes accompanied by the measure of association for the outcomes. EXPECTED RESULTS: Update the evidence regarding the risk of complications in diabetic patients with COVID-19 and in turn synthesize the information available regarding type 1 and type 2 diabetes mellitus, to provide keys to a better understanding of the pathophysiology of diabetics. SYSTEMATIC REVIEW REGISTRY: This study was registered at the International Prospective Registry for Systematic Reviews (PROSPERO)-CRD42021231942.